Sotera Health (SHC) Hisse Özeti
Sotera Health Company, Amerika Birleşik Devletleri, Kanada, Avrupa ve uluslararası alanda sağlık sektörü için sterilizasyon çözümleri, laboratuvar testleri ve danışmanlık hizmetleri sunmaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 2/6 |
| Temettüler | 0/6 |
SHC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sotera Health Company Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$17.99 |
| 52 Haftanın En Yüksek Seviyesi | US$19.85 |
| 52 Haftanın En Düşük Seviyesi | US$11.00 |
| Beta | 1.78 |
| 1 Aylık Değişim | 0.33% |
| 3 Aylık Değişim | 13.86% |
| 1 Yıllık Değişim | 60.77% |
| 3 Yıllık Değişim | 4.78% |
| 5 Yıllık Değişim | -24.35% |
| Halka arzdan bu yana değişim | -28.33% |
Son Haberler & Güncellemeler
Seeking Alpha • Jul 24
Sotera Health: Why We Plan To Own This For Many Years
Summary Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 25
SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside
The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.Anlatı Güncellemesi • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.Recent updates
Seeking Alpha • Jul 24
Sotera Health: Why We Plan To Own This For Many Years
Summary Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 25
SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside
The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.Anlatı Güncellemesi • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.Analiz Makalesi • May 13
Sotera Health's (NASDAQ:SHC) Performance Is Even Better Than Its Earnings Suggest
Sotera Health Company ( NASDAQ:SHC ) just reported healthy earnings but the stock price didn't move much. Investors are...Anlatı Güncellemesi • May 12
SHC: Equity Raise And Reaffirmed 2026 Guidance Will Support Upside
Analysts have trimmed their price target on Sotera Health slightly from $20.50 to $20.13, citing updated assumptions for long term revenue growth, profit margins, and future P/E multiples. What's in the News Sotera Health plans a CEO transition, with Alton Shader set to become CEO and join the board on May 26, 2026.Anlatı Güncellemesi • Apr 27
SHC: Follow On Equity Raise And 2026 Guidance Will Support Upside
Analysts now see a slightly lower price target for Sotera Health, trimming it from $20.75 to $20.50 as small adjustments to fair value, discount rate, revenue growth, profit margin and forward P/E estimates feed into their updated view. What's in the News Sotera Health completed a follow-on equity offering of 25,000,000 common shares, raising about US$381.75m at a price of US$15.27 per share (Key Developments).Anlatı Güncellemesi • Apr 10
SHC: Equity Raise And 2026 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their $20.75 price target on Sotera Health, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions underpinning the updated view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 common shares, raising about $381.75 million at a price of $15.27 per share (company filing).Anlatı Güncellemesi • Mar 27
SHC: Equity Raise And 2026 Guidance Will Support Future Upside Potential
Analysts are maintaining a price target of $20.75 for Sotera Health, with only modest tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E multiples, supporting an unchanged valuation view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 shares of common stock, raising approximately $381.75 million at a price of about $15.27 per share (company filing).Anlatı Güncellemesi • Mar 10
SHC: Organic Investment And Margin Expansion Will Support Future Upside Potential
Analysts have raised their price target on Sotera Health to $20.75 from $20.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect refreshed views on the company’s risk profile and earnings power. What's in the News Sotera Health filed a follow on equity offering of 25,000,000 shares of common stock, and later completed the offering for proceeds of US$381.75m at a price of US$15.27 per share, indicating recent access to equity capital markets.Anlatı Güncellemesi • Feb 24
SHC: Organic Investment And Deleveraging Will Support Future Upside Potential
Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.Anlatı Güncellemesi • Feb 10
SHC: Organic Capital Deployment Will Support Deleveraging And Undervalued Upside
Analysts have maintained their price target for Sotera Health at approximately US$20.44, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E used in their valuation models. What's in the News Sotera Health signaled it will continue to focus its capital on organic growth initiatives, with CEO Michael Petras highlighting this as the primary use of funds during the JPMorgan Healthcare Conference (Key Developments).Anlatı Güncellemesi • Jan 26
SHC: Equity Offering And Capital Allocation Priorities Will Guide Balanced Outlook
Analysts have modestly adjusted their price expectations for Sotera Health, with the updated target now at approximately US$20.44. This reflects small tweaks to assumptions such as the discount rate, long-term revenue growth, profit margin and future P/E.
Yeni Anlatı • Jan 24
Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside
Catalysts About Sotera Health Sotera Health provides sterilization services and lab testing that support global health care and medical products. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Jan 12
SHC: Follow-On Equity Offering And Lock-Up Terms Will Shape Balanced Outlook
Analysts have lifted their price target for Sotera Health to US$20.44 from US$18.93, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Sotera Health completed a follow on equity offering of 30,000,000 common shares, raising about US$471 million at a price of US$15.70 per share with a US$0.049 discount per share (Key Developments).Analiz Makalesi • Jan 09
Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?
Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...Anlatı Güncellemesi • Dec 15
SHC: Follow-On Equity Offering Will Drive Bullish Share Performance Next Year
Narrative Update Analysts have modestly raised their price target on Sotera Health, citing fine tuned assumptions around discount rates, revenue growth, margins, and future earnings multiples as justification for a slightly higher implied fair value near $18.93 per share. What's in the News Sotera Health has completed a follow-on equity offering of approximately $471 million, issuing 30 million shares of common stock at about $15.70 per share (Key Developments) The company has filed a separate follow-on equity offering totaling roughly $480.3 million for 30 million shares of common stock, with an indicated price of about $16.01 per share (Key Developments) Executive officers, directors and selling stockholders have agreed to a lock-up on 284,093,929 common shares, restricting most sales and hedging activity from November 6, 2025 to December 7, 2025 (Key Developments) Certain restricted stock units held by insiders are also subject to the same 31-day lock-up period ending December 7, 2025 (Key Developments) Options held by executives, directors and selling stockholders will likewise be restricted during the November 6 to December 7, 2025 lock-up window (Key Developments) Valuation Changes Fair Value: Unchanged at an implied price of approximately $18.93 per share.Anlatı Güncellemesi • Nov 30
SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year
Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios. What's in the News Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).Anlatı Güncellemesi • Nov 16
SHC: Improved Profit Margins Will Drive Future Share Price Upside
Analysts have raised their price target for Sotera Health from $17.00 to $18.93 per share. They cite an improved profit margin outlook despite slightly lower revenue growth projections.Analiz Makalesi • Nov 11
Sotera Health's (NASDAQ:SHC) Conservative Accounting Might Explain Soft Earnings
The most recent earnings report from Sotera Health Company ( NASDAQ:SHC ) was disappointing for shareholders. However...Analiz Makalesi • Nov 07
Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts
Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...Anlatı Güncellemesi • Nov 01
SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook
Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.Anlatı Güncellemesi • Oct 17
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.Anlatı Güncellemesi • Oct 03
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.Analiz Makalesi • Aug 13
After Leaping 26% Sotera Health Company (NASDAQ:SHC) Shares Are Not Flying Under The Radar
Sotera Health Company ( NASDAQ:SHC ) shareholders would be excited to see that the share price has had a great month...Anlatı Güncellemesi • Aug 10
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.
Yeni Anlatı • Sep 02
Sterigenics' Expansion And Smart Pricing Poised For Sustained Revenue And Margin Growth
Sotera Health's strategic pricing and capacity expansion reflect confidence in maintaining or growing future revenue and net margins, despite economic pressures.Hissedar Getirileri
| SHC | US Life Sciences | US Pazar | |
|---|---|---|---|
| 7D | 1.3% | -0.3% | 2.4% |
| 1Y | 60.8% | 20.5% | 19.6% |
Getiri vs. Endüstri: SHC geçen yıl % 20.5 oranında getiri sağlayan US Life Sciences sektörünü aştı.
Getiri vs Piyasa: SHC geçen yıl % 19.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 4.2% |
| Life Sciences Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
İstikrarlı Hisse Senedi Fiyatı: SHC son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: SHC 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2015 | 3,000 | Alton Shader | soterahealth.com |
Sotera Health Company, Amerika Birleşik Devletleri, Kanada, Avrupa ve uluslararası alanda sağlık sektörü için sterilizasyon çözümleri, laboratuvar testleri ve danışmanlık hizmetleri sunmaktadır. Şirket üç segmentte faaliyet göstermektedir: Sterigenics, Nordion ve Nelson Labs. Sterigenics segmenti, tıbbi cihazlar, ilaç, gıda güvenliği ve gelişmiş uygulamalar pazarları için gama ışınlama, etilen oksit işleme ve elektron ışını ışınlama teknolojilerini kullanarak dış kaynaklı terminal sterilizasyon ve ışınlama hizmetleri sunmaktadır.
Sotera Health Company Temel Bilgiler Özeti
| SHC temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$5.13b |
| Kazançlar(TTM) | US$117.79m |
| Gelir(TTM) | US$1.19b |
43.6x
F/K Oranı4.3x
P/S OranıSHC aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| SHC gelir tablosu (TTM) | |
|---|---|
| Gelir | US$1.19b |
| Gelir Maliyeti | US$531.97m |
| Brüt Kâr | US$657.17m |
| Diğer Giderler | US$539.38m |
| Kazançlar | US$117.79m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
Aug 06, 2026
| Hisse başına kazanç (EPS) | 0.41 |
| Brüt Marj | 55.26% |
| Net Kâr Marjı | 9.91% |
| Borç/Özkaynak Oranı | 343.5% |
SHC uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/04 06:18 |
| Gün Sonu Hisse Fiyatı | 2026/08/03 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Sotera Health Company 13 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |